PT  - JOURNAL ARTICLE
AU  - Patel, Monila
AU  - Lakhotia, Yogesh
AU  - Shah, Sneha
AU  - Suthar, Nilay
AU  - Shah, Cherry
AU  - Kola, Sankarrao
AU  - Rangarajan, Radha
TI  - Clinical validation of a point-of-care antibody test for COVID-19
AID  - 10.1101/2020.12.16.20248303
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.12.16.20248303
4099  - http://medrxiv.org/content/early/2020/12/18/2020.12.16.20248303.short
4100  - http://medrxiv.org/content/early/2020/12/18/2020.12.16.20248303.full
AB  - The objective of this study was to evaluate the performance of a lateral flow antibody test for COVID-19, approved for use in India. Although many point-of-care antibody tests are available globally, they have been subjected to limited clinical validation. This has led to suboptimal outcomes in the field, where antibody tests play a significant role in tracking the immunity of individuals and communities. In this study an antibody test, ImmunoQuick that recognizes antibodies to the Nucleocapsid and Spike proteins of SARS CoV-2 was tested in 100 symptomatic patients with a positive or negative diagnosis of COVID-19, based on RT-PCR results. The overall sensitivity of the test was found to be 86.1% (95% CI: 76.4% to 92.8%) and specificity 100% (95% confidence interval: 73.5% to 100%). The sensitivity reached a peak of 95.7% with samples taken 17 days after the onset of symptoms. Overall, the sensitivity and specificity of the test are sufficient for assessing seroprevalence.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI/2020/07/026469Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Name of Committee: NHL Municipal Medical College Date of Approval: 29/06/20 Approval letter can be provided on demandAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data referred to in the manuscript was collected in the clinical study. No external data is being published in the manuscript.